GlassScriptPhysician profile
Kellie D Spector
NPI 1700374469
$11,018.41
in general payments reported to CMS, 2019-2025
62 companies · $5,420 in 2025
The $5,420 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $25.52 · 2021: $123 · 2022: $807 · 2023: $1,942 · 2024: $2,701 · 2025: $5,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,479 · Consulting Fee: $1,088 · Education: $497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,478.95 |
| Consulting Fee | $1,087.50 |
| Education | $496.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,153.71 | 2025 | Jemperli, Ojjaara |
| Seagen INC. | $1,081.59 | 2022-2023 | Tukysa, Adcetris |
| Astrazeneca Pharmaceuticals LP | $587.07 | 2023-2025 | Enhertu, Lynparza, Calquence |
| Daiichi Sankyo INC. | $493.44 | 2024-2025 | Enhertu, Datroway |
| Incyte Corporation | $462.62 | 2023-2025 | Monjuvi, Jakafi, Pemazyre |
| Regeneron Healthcare Solutions, INC. | $447.45 | 2024-2025 | Libtayo |
| Janssen Biotech, INC. | $440.53 | 2024-2025 | Tecvayli, Rybrevant, Darzalex |
| Genzyme Corporation | $439.55 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $344.11 | 2024-2025 | Opdivo, Opdualag, Pomalyst |
| Eisai INC. | $343.77 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $323.60 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $306.13 | 2023-2025 | Rylaze, Defitelio |
| Beone Medicines USA, INC. | $298.54 | 2025 | Brukinsa, Tevimbra |
| Pfizer INC. | $264.16 | 2024-2025 | |
| Astellas Pharma US INC | $251.70 | 2023-2025 | Xospata, Vyloy |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $251.01 | 2022-2025 | Trodelvy |
| Amgen INC. | $244.14 | 2020-2025 | |
| Celgene Corporation | $236.02 | 2021-2025 | Opdivo, Pomalyst, Opdualag |
| Janssen Scientific Affairs, LLC | $224.05 | 2025 | Rybrevant |
| Merck Sharp & Dohme LLC | $209.79 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Genentech USA, INC. | $198.50 | 2024-2025 | Polivy, Itovebi, Tecentriq Hybreza |
| Abbvie INC. | $175.68 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $156.46 | 2024-2025 | Somatuline Depot, Onivyde |
| Sobi, INC | $154.65 | 2024-2025 | |
| Beigene USA, INC. | $123.35 | 2024-2025 | Brukinsa |
| Lilly USA, LLC | $107.78 | 2024-2025 | Jaypirca, Verzenio |
| Genmab U.S., INC. | $107.58 | 2024-2025 | Epkinly |
| Stemline Therapeutics INC. | $101.62 | 2023-2025 | Elzonris, Orserdu |
| Array Biopharma INC | $97.44 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Bayer Healthcare Pharmaceuticals INC. | $96.49 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $87.90 | 2023-2025 | Xpovio |
| Puma Biotechnology, INC. | $81.43 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.90 | 2024 | Gilotrif |
| Taiho Oncology, INC. | $75.80 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $69.99 | 2023 | |
| Alexion Pharmaceuticals, INC. | $68.42 | 2023-2024 | Ultomiris |
| Mirati Therapeutics, INC. | $62.23 | 2023-2024 | Krazati |
| Ge Healthcare | $60.02 | 2025 | |
| Springworks Therapeutics, INC. | $55.16 | 2025 | Ogsiveo |
| Iovance Biotherapeutics, INC. | $54.13 | 2025 | Amtagvi |
| Coherus Oncology, INC. | $53.61 | 2024-2025 | Loqtorzi |
| Foundation Medicine, INC. | $46.07 | 2023 | |
| Rigel Pharmaceuticals, INC. | $44.44 | 2024-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Exelixis INC. | $37.94 | 2025 | Cabometyx |
| Emd Serono, INC. | $33.48 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $30.56 | 2025 | |
| Caris Mpi, INC. | $29.34 | 2025 | Mi Cancer Seek |
| Immunogen, INC. | $29.21 | 2023 | Elahere |
| Tersera Therapeutics LLC | $28.70 | 2023 | Xermelo |
| Adc Therapeutics America, INC. | $28.24 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.66 | 2025 | |
| Kyowa Kirin, INC. | $25.18 | 2025 | |
| Fennec Pharmaceuticals, INC. | $24.63 | 2025 | Fyarro |
| Verity Pharmaceuticals INC. | $24.26 | 2025 | Trelstar |
| Deciphera Pharmaceuticals INC. | $24.14 | 2025 | Qinlock |
| Sumitomo Pharma America, INC. | $23.60 | 2025 | Orgovyx |
| Helsinn Therapeutics (U.S.), INC. | $18.07 | 2025 | Akynzeo |
| Cumberland Pharmaceuticals, INC. | $17.45 | 2025 | Sancuso |
| Tolmar, INC. | $15.17 | 2024 | |
| Pharmaessentia USA Corporation | $14.27 | 2025 | Besremi |
| Myriad Genetic Laboratories, INC. | $13.95 | 2023 | Myrisk |
| Accord Healthcare, INC. | $13.93 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellie Spector listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.